The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma

Author:

Coulson Rhiannon12,Liew Seng H.3,Connelly Angela A.4,Yee Nicholas S.5,Deb Siddhartha6,Kumar Beena7,Vargas Ana C.8,O’Toole Sandra A.829,Parslow Adam C.1011,Poh Ashleigh12,Putoczki Tracy12,Morrow Riley J.5,Alorro Mariah5,Lazarus Kyren A.113,Yeap Evie F.W.1,Walton Kelly L.14,Harrison Craig A.14,Hannan Natalie J.15,George Amee J.16,Clyne Colin D.1,Ernst Matthias511,Allen Andrew M.4,Chand Ashwini L.1511

Affiliation:

1. Cancer Drug Discovery, Hudson’s Institute of Medical Research, Clayton, VIC, Australia

2. Translational Breast Cancer Research, Garvan Institute, Darlinghurst, Sydney, NSW, Australia

3. Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia

4. Department of Physiology, University of Melbourne, VIC, Australia

5. Cancer and Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia

6. Anatomical Pathology, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia

7. Anatomical Pathology, Monash Health, Clayton, VIC, Australia

8. Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, NSW, Australia

9. Sydney Medical School, Sydney University, NSW, Australia

10. Tumor Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia

11. School of Cancer Medicine, La Trobe University, Heidelberg, VIC, Australia

12. Inflammation Division, WEHI, VIC, Australia

13. Department of Pharmacology, University of Cambridge, Cambridge, UK

14. Department of Physiology, Monash University, Clayton, VIC, Australia

15. Translational Obstetrics Group, Department of Obstetrics and Gynaecology, University of Melbourne, Mercy Hospital, Heidelberg, VIC, Australia

16. The ACRF Department of Cancer Biology and Therapeutics, John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia

Publisher

Impact Journals, LLC

Subject

Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3